Discover
KPTI
Karyopharm Therapeutics Inc.
9.55
1 x 8.23
1 x 11.04
bid
ask
-
0.22
2.25%
1 @ 05:21 AM
9.65 +0.10 (1.05%)
| Ytd | 29.76% | |
| 1y | 119.04% |
9.34
day range
9.83
3.65
52 week range
10.99
| Open | 9.68 | Prev Close | 9.77 | Low | 9.34 | High | 9.83 | Mkt Cap | 216.43M |
| Vol | 306.62K | Avg Vol | 491.15K | EPS | -16.40 | P/E | N/A | Forward P/E | -0.87 |
| Beta | 0.15 | Short Ratio | 19.48 | Inst. Own | 48.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.94 | 200-d Avg | 7.40 | 1yr Est | 4.50 |
KPTI News
prnewswire.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercia
benzinga.com
Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
benzinga.com
Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentatio
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie